Targeting p21<sup>Cip1</sup> highly expressing cells in adipose tissue alleviates insulin resistance in obesity.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 34813734.
- Also identified by DOI 10.1016/j.cmet.2021.11.002 and PMC identifier 8732323.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Insulin resistance is a pathological state often associated with obesity, representing a major risk factor for type 2 diabetes. Limited mechanism-based strategies exist to alleviate insulin resistance. Here, using single-cell transcriptomics, we identify a small, critically important, but previously unexamined cell population, p21<sup>Cip1</sup> highly expressing (p21<sup>high</sup>) cells, which accumulate in adipose tissue with obesity. By leveraging a p21-Cre mouse model, we demonstrate that intermittent clearance of p21<sup>high</sup> cells can both prevent and alleviate insulin resistance in obese mice. Exclusive inactivation of the NF-κB pathway within p21<sup>high</sup> cells, without killing them, attenuates insulin resistance. Moreover, fat transplantation experiments establish that p21<sup>high</sup> cells within fat are sufficient to cause insulin resistance in vivo. Importantly, a senolytic cocktail, dasatinib plus quercetin, eliminates p21<sup>high</sup> cells in human fat ex vivo and mitigates insulin resistance following xenotransplantation into immuno-deficient mice. Our findings lay the foundation for pursuing the targeting of p21<sup>high</sup> cells as a new therapy to alleviate insulin resistance.
Medical subject headings
- Diabetes Mellitus, Type 2
- Insulin Resistance